These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38946010)

  • 21. Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension: a meta-analysis of randomized trials.
    Hu J; Zhou Y
    Blood Press; 2023 Dec; 32(1):2242501. PubMed ID: 37652401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacotherapy for hypertension-induced left ventricular hypertrophy.
    Leache L; Gutiérrez-Valencia M; Finizola RM; Infante E; Finizola B; Pardo Pardo J; Flores Y; Granero R; Arai KJ
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD012039. PubMed ID: 34628642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT).
    Ruggenenti P; Iliev I; Costa GM; Parvanova A; Perna A; Giuliano GA; Motterlini N; Ene-Iordache B; Remuzzi G;
    Diabetes Care; 2008 Aug; 31(8):1629-34. PubMed ID: 18443191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
    Okin PM; Hille DA; Kjeldsen SE; Devereux RB
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29151037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension.
    Pierdomenico SD; Lapenna D; Cuccurullo F
    Am J Hypertens; 2008 Apr; 21(4):464-70. PubMed ID: 18369364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electrocardiographic left ventricular hypertrophy and mortality in an oldest-old hypertensive Chinese population.
    Chen R; Bai K; Lu F; Zhao Y; Pan Y; Wang F; Zhang L
    Clin Interv Aging; 2019; 14():1657-1662. PubMed ID: 31571845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is Left Ventricular Hypertrophy a Valid Therapeutic Target?
    Brooks JE; Soliman EZ; Upadhya B
    Curr Hypertens Rep; 2019 May; 21(6):47. PubMed ID: 31111289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Anemia on Cardiovascular Events and All-Cause Death Among Participants Who Received Intense Blood Pressure Treatment: A Secondary Analysis of SPRINT.
    Liu X; Lin B; Yao S; Pan Z
    Rev Cardiovasc Med; 2024 Jan; 25(1):6. PubMed ID: 39077655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between Intensive vs Standard Blood Pressure Control and Incident Left Ventricular Conduction Disease: A Post Hoc Analysis of the SPRINT Randomized Clinical Trial.
    Frimodt-Møller EK; Vittinghoff E; Kaur G; Biering-Sørensen T; Soliman EZ; Marcus GM
    JAMA Cardiol; 2023 Jun; 8(6):612-616. PubMed ID: 37133829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.
    Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Marx N; Sliwa K; Weber MA; Williams B; Yusuf S
    Eur Heart J; 2019 Jul; 40(25):2032-2043. PubMed ID: 30919899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Intensive Blood Pressure Control and Living Arrangement on Cardiovascular Outcomes by Race: Post Hoc Analysis of SPRINT Randomized Clinical Trial.
    Inoue K; Watson KE; Kondo N; Horwich T; Hsu W; Bui AAT; Duru OK
    JAMA Netw Open; 2022 Mar; 5(3):e222037. PubMed ID: 35285922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the  RE - LY Trial.
    Hijazi Z; Verdecchia P; Oldgren J; Andersson U; Reboldi G; Di Pasquale G; Mazzotta G; Angeli F; Eikelboom JW; Ezekowitz MD; Connolly SJ; Yusuf S; Wallentin L
    J Am Heart Assoc; 2019 Jan; 8(2):e010107. PubMed ID: 30651032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Four ECG left ventricular hypertrophy criteria and the risk of cardiovascular events and mortality in patients with vascular disease.
    van Kleef MEAM; Visseren FLJ; Vernooij JWP; Nathoe HM; Cramer MM; Bemelmans RHH; van der Graaf Y; Spiering W;
    J Hypertens; 2018 Sep; 36(9):1865-1873. PubMed ID: 29878973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Left Ventricular Hypertrophy Does Not Affect 1-Year Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement.
    Varshney AS; Manandhar P; Vemulapalli S; Kirtane AJ; Mathew V; Shah B; Lowenstern A; Kosinski AS; Kaneko T; Thourani VH; Bhatt DL
    JACC Cardiovasc Interv; 2019 Feb; 12(4):373-382. PubMed ID: 30784643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
    Okin PM; Wachtell K; Gerdts E; Dahlöf B; Devereux RB
    J Hypertens; 2014 Dec; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects.
    Verdecchia P; Angeli F; Gattobigio R; Sardone M; Pede S; Reboldi GP
    Am J Hypertens; 2006 May; 19(5):493-9. PubMed ID: 16647622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum bicarbonate and cardiovascular events in hypertensive adults: results from the Systolic Blood Pressure Intervention Trial.
    Dobre M; Pajewski NM; Beddhu S; Chonchol M; Hostetter TH; Li P; Rahman M; Servilla K; Weiner DE; Wright JT; Raphael KL;
    Nephrol Dial Transplant; 2020 Aug; 35(8):1377-1384. PubMed ID: 32163578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical benefit of systolic blood pressure within the target range among patients with or without diabetes mellitus: a propensity score-matched analysis of two randomized clinical trials.
    Li C; Chen K; Shi G; Shi R; Wu Z; Yuan X; Watson V; Jiang Z; Mai H; Yang T; Wang D; Chen T
    BMC Med; 2022 Jun; 20(1):208. PubMed ID: 35718771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of a 4-Tiered Classification of LV Hypertrophy With Adverse CV Outcomes in the General Population.
    Garg S; de Lemos JA; Ayers C; Khouri MG; Pandey A; Berry JD; Peshock RM; Drazner MH
    JACC Cardiovasc Imaging; 2015 Sep; 8(9):1034-1041. PubMed ID: 26298074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.